RH and its effect on drug attributes

Published: 16-Sep-2014

Water's relationship to APIs is complex and can spell disaster for some drug formulations. Andrew Parker, Molecular Profiles, and Michael Leane, Bristol-Myers Squibb, look at the need to control relative humidity during various production processes

You need to be a subscriber to read this article.
Click here to find out more.

Humidity can be expressed as an absolute, specific or relative value. In the pharmaceutical community, the latter is generally used when controlling humidity; for example, either in stress stability studies performed to ICH conditions (e.g. 25°C/75% RH accelerated storage or 25°C/60% RH real time condition); or a manufacturing process step such as dry blending.

RH can be expressed as the ratio of the vapour partial pressure of the air to the saturation vapour partial pressure of the air at the actual dry bulb temperature. Hence, there is a different amount of water vapour per unit volume at, for example, 50% RH at 15°C compared with 25°C. Even over such a small temperature difference, the amount of water the air can hold increases by a factor of 1.8. Thus, even small differences in temperature can dramatically affect humidity sensitive processes.

In pharmaceutical manufacture, the need to control humidity may not be just to ensure stability of the API and prevent any degradation due to hydrolysis, for example, but also to ensure that quality drug products with respect to other critical quality attributes1 are produced.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like